AZD 2115

Drug Profile

AZD 2115

Alternative Names: AZD-2115

Latest Information Update: 04 Apr 2017

Price : $50

At a glance

  • Originator AstraZeneca; Pulmagen Therapeutics
  • Developer AstraZeneca
  • Class Antiasthmatics; Bronchodilators; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 04 Apr 2017 AstraZeneca plans a phase I trial in Healthy volunteers in Sweden (NCT03097380)
  • 31 Mar 2015 Discontinued - Phase-I for Chronic obstructive pulmonary disease (In volunteers) in United Kingdom (Inhalation)
  • 31 Mar 2015 Discontinued - Phase-II for Chronic obstructive pulmonary disease in USA, Poland and Sweden (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top